全文获取类型
收费全文 | 535437篇 |
免费 | 32651篇 |
国内免费 | 1500篇 |
专业分类
耳鼻咽喉 | 6749篇 |
儿科学 | 16395篇 |
妇产科学 | 14710篇 |
基础医学 | 75503篇 |
口腔科学 | 11922篇 |
临床医学 | 48505篇 |
内科学 | 105560篇 |
皮肤病学 | 9622篇 |
神经病学 | 45037篇 |
特种医学 | 21968篇 |
外国民族医学 | 56篇 |
外科学 | 84264篇 |
综合类 | 10486篇 |
现状与发展 | 2篇 |
一般理论 | 344篇 |
预防医学 | 36816篇 |
眼科学 | 12400篇 |
药学 | 36962篇 |
29篇 | |
中国医学 | 1157篇 |
肿瘤学 | 31101篇 |
出版年
2022年 | 3292篇 |
2021年 | 7827篇 |
2020年 | 4618篇 |
2019年 | 7594篇 |
2018年 | 10263篇 |
2017年 | 7421篇 |
2016年 | 8426篇 |
2015年 | 9787篇 |
2014年 | 13503篇 |
2013年 | 19149篇 |
2012年 | 26681篇 |
2011年 | 27395篇 |
2010年 | 16555篇 |
2009年 | 15123篇 |
2008年 | 24513篇 |
2007年 | 26134篇 |
2006年 | 25484篇 |
2005年 | 24944篇 |
2004年 | 23661篇 |
2003年 | 21746篇 |
2002年 | 20735篇 |
2001年 | 15271篇 |
2000年 | 15183篇 |
1999年 | 13485篇 |
1998年 | 5849篇 |
1997年 | 5027篇 |
1996年 | 4557篇 |
1995年 | 4291篇 |
1994年 | 3862篇 |
1993年 | 3695篇 |
1992年 | 9299篇 |
1991年 | 9419篇 |
1990年 | 9066篇 |
1989年 | 8836篇 |
1988年 | 7996篇 |
1987年 | 7696篇 |
1986年 | 7359篇 |
1985年 | 7198篇 |
1984年 | 5675篇 |
1983年 | 4898篇 |
1982年 | 3491篇 |
1981年 | 3009篇 |
1979年 | 4889篇 |
1978年 | 3733篇 |
1977年 | 3174篇 |
1975年 | 3154篇 |
1974年 | 3665篇 |
1973年 | 3627篇 |
1972年 | 3300篇 |
1971年 | 3110篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kamolz Lars-Peter Kotzbeck Petra Schintler Michael Spendel Stephan 《European Surgery》2022,54(3):163-169
European Surgery - Large skin defects caused by trauma (e.g., burns) or due to other reasons (e.g., tumor-related skin resections) require sufficient skin replacement. The constant improvement of... 相似文献
2.
3.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
4.
5.
6.
7.
8.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
9.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献